The microneutralization assay is a powerful, high-throughput screening tool crucial to the efficient development of novel vaccines and the discovery of compounds that can prevent or treat viral disease.
Between preventative vaccines and palliative treatment for the sickest COVID-19 patients lies the realm of existing drugs that could be repurposed for antiviral prophylaxis.
During this webinar, Dr. Suzanne Riches highlights a variety of approaches for conducting virology assays in a high-throughput format.
Fast track vaccine development process by conducting assays in 96- or 384-well plates based on enumeration of foci, plaque or single infected cells.
Nexcelom's China team works with scientists in State Key Laboratory of Respiratory Diseases in China, for the screening of antiviral agents against SARS-CoV-2 virus, the cause of COVID-19 (Corona Virus).
Improved fluorescent plaque assay method using fluorescently-labeled antibodies and the use of the Celigo image cytometer.
Come visit us at booth #413 Merck Technology Symposium 2018 September 5-6, 2018 Ocean Place Resort Long Branch, NJ Posters being presented: High-throughput foci counting of viral titer and antibody neutralization assays using the Celigo Image Cytometer for developing a novel cross-reactive influenza vaccine Long-term time-course monitoring of NK cell-mediated ADCC using the Celigo Image Cytometer A high-throughput 3D tumor spheroid screening method for drug discovery using imaging cytometry
